Today, there is an increasingly complex and fragmented life sciences regulatory landscape, which is struggling to keep pace with the exponential changes in medicine, science and technology while protecting patient safety.
However, this latest predictions report from the Deloitte UK Centre for Health Solutions shows a bold future for regulation in the life sciences industry. One in which collaborative working between the regulator and industry, enabled by developing technologies, supports positive and innovative outcomes for patients.
Our four key predictions for life sciences regulation in 2025 are brought to life by imagining how regulators, industry and patients might behave in this new world. We purposefully present an optimistic view of the future, designed to enable industry leaders to grasp the disruption and transformation opportunities that lie ahead.
Achieving this more positive vision of the future and delivering better outcomes for patients will require regulators and the industry to:
Indeed, the skill set and engagement strategies of regulators will look quite different from today, and life science companies will need to re-programme their regulation mind-set to create a new, more collaborative environment that drives a culture change across the industry. This is a future in which patients are fully engaged in designing regulations, companies are truly patient-centric and the regulatory function of each life science company has moved from being a back-office enabler to a strategic business partner.